Who is sponsoring NCT03426748?

NCT03426748 is sponsored by British Columbia Cancer Agency.

What drugs are being tested in NCT03426748?

Interventions in NCT03426748: Low dose rate prostate brachytherapy, High dose rate prostate brachytherapy.

What condition does NCT03426748 study?

NCT03426748 studies Prostate Cancer.

Is NCT03426748 still recruiting?

NCT03426748 is currently active, enrolled. Last updated 29 January 2026.

Last reviewed 2026-01-29 · How we verify

NCT03426748: LDR/HDRmono

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LDR vs. HDR Brachytherapy for Prostate Cancer

Active, enrolled NA Last updated 29 January 2026

What this trial tests

NA trial testing Low dose rate prostate brachytherapy in Prostate Cancer in 140 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 February 2018

Primary endpoint
31 August 2026

31 October 2034

Quick facts

Lead sponsor	British Columbia Cancer Agency
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	140
Start date	15 February 2018
Primary completion	31 August 2026
Estimated completion	31 October 2034
Sites	1 location across Canada

Drugs / interventions tested

Low dose rate prostate brachytherapy
High dose rate prostate brachytherapy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

British Columbia Cancer Agency

Who can join

Adults 40 to 80, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

H17-02904 is a randomized comparison of low dose rate vs. high dose rate prostate brachytherapy for favorable and intermediate risk prostate cancer suitable for brachytherapy as monotherapy. This is a continuation with expanded accrual of the randomized Pilot study H15-02103

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions.
Wei S, Li C, Li M, Xiong Y, et al · · 2021 · cited 38× · PMID 34660280 · DOI 10.3389/fonc.2021.717180
A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy.
Slevin F, Rodda SL, Bownes P, Murray L, et al · · 2020 · cited 15× · PMID 31701035 · DOI 10.1016/j.ctro.2019.10.001
Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy.
Ma TM, Lilleby O, Lilleby WA, Kishan AU. · · 2020 · cited 5× · PMID 33276562 · DOI 10.3390/cancers12123606
Modelling of immune infiltration in prostate cancer treated with HDR-brachytherapy using Raman spectroscopy and machine learning.
Popescu SN, Milligan K, Wiebe M, Fuentes A, et al · · 2025 · PMID 41102259 · DOI 10.1038/s41598-025-20107-5

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other British Columbia Cancer Agency trials

Trials by the same sponsor.

NCT07295171 — HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG · NA · recruiting
NCT07291895 — High Dose Radiotherapy for Palliation (Hi-D) · NA · not yet recruiting
NCT06918951 — Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers · NA · recruiting
NCT07210749 — Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma · NA · not yet recruiting
NCT06835725 — Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prost · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03426748 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by British Columbia Cancer Agency
Last refreshed: 29 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03426748.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing